Efficacy News and Research

RSS
Arthritis drug reduces dry eye disease

Arthritis drug reduces dry eye disease

SCCA pioneers new transplant procedures to reduce need for matching bone marrow donors

SCCA pioneers new transplant procedures to reduce need for matching bone marrow donors

SironRX completes enrollment in Cohort 1 to study JVS-100 for wound healing, scar prevention

SironRX completes enrollment in Cohort 1 to study JVS-100 for wound healing, scar prevention

FDA agrees to allow ADial to move forward with Phase III trial of AD04 for alcohol use disorder

FDA agrees to allow ADial to move forward with Phase III trial of AD04 for alcohol use disorder

Clinical data of EV71 vaccine for prevention of HFMD presented at World Vaccine Congress & Expo

Clinical data of EV71 vaccine for prevention of HFMD presented at World Vaccine Congress & Expo

Longer looks: The timely trauma response in Boston; Problems with aging doctors; Transplants from donors with HIV

Longer looks: The timely trauma response in Boston; Problems with aging doctors; Transplants from donors with HIV

Patient enrollment underway in Phase III trial program to evaluate amikacin inhalation solution

Patient enrollment underway in Phase III trial program to evaluate amikacin inhalation solution

New assays are effective in managing patients with influenza virus infection

New assays are effective in managing patients with influenza virus infection

Study: Shock wave-facilitated cell therapy improves outcomes in patients with chronic heart failure

Study: Shock wave-facilitated cell therapy improves outcomes in patients with chronic heart failure

FDA's PADAC supports approval of BREO ELLIPTA as once-daily inhaled treatment for COPD

FDA's PADAC supports approval of BREO ELLIPTA as once-daily inhaled treatment for COPD

Eli Lilly reports positive results from Phase III AWARD trials of type 2 diabetes drug, dulaglutide

Eli Lilly reports positive results from Phase III AWARD trials of type 2 diabetes drug, dulaglutide

Mast Therapeutics' data show that MST-188 reduces aggregation of both older and younger RBC

Mast Therapeutics' data show that MST-188 reduces aggregation of both older and younger RBC

Preclinical studies show bladder cancers, mesotheliomas respond to treatment with ADI-PEG 20

Preclinical studies show bladder cancers, mesotheliomas respond to treatment with ADI-PEG 20

Phase III clinical trial data of Milprosa vaginal ring presented at PCRS annual meeting

Phase III clinical trial data of Milprosa vaginal ring presented at PCRS annual meeting

Primary mediastinal B-cell lymphoma has better outcome with more dose-intense regimens

Primary mediastinal B-cell lymphoma has better outcome with more dose-intense regimens

Phase IIa study shows safety and efficacy of BL-7040 in treating ulcerative colitis

Phase IIa study shows safety and efficacy of BL-7040 in treating ulcerative colitis

Santarus, Pharming Group submit Biologics License Application to FDA for RUCONEST

Santarus, Pharming Group submit Biologics License Application to FDA for RUCONEST

UI Health to launch EPIC program to cut frequent ER visits, readmissions to hospital

UI Health to launch EPIC program to cut frequent ER visits, readmissions to hospital

Flunisyn Phase 2a trial data shows positive results in elderly population

Flunisyn Phase 2a trial data shows positive results in elderly population

GlycoMimetics reports Phase 2 clinical study results of GMI-1070

GlycoMimetics reports Phase 2 clinical study results of GMI-1070

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.